ABIVAX press release
Dr. June Lee and Troy Ignelzi are appointed members of the Abivax Board of Directors.
Abivax SA, a Phase 3 clinical-stage biotechnology company developing immune-modulating drugs to treat patients with chronic inflammatory diseases, today announces the appointment of Dr. June Lee, MD, and Troy Ignelzi as new independent members of the Abivax Board of Directors. June Lee and Troy Ignelzi replace Joy Amundson and Jean-Jacques Bertrand who are stepping down as members of the Board of Directors.